The Infectious Diseases Society of America supports the CDC Advisory Committee on Immunization Practice’s unanimous recommendation to allow “mix-and-match”—or heterologous—COVID-19 booster shots for at-risk populations. 

IDSA and HIVMA applaud the bipartisan introduction of the Bolstering Infectious Outbreaks (BIO) Preparedness Workforce Act by Reps. Lori Trahan (D-MA) and David McKinley (R-WV), H.R. 5602, and its inclusion in an Oct. 26 Energy and Commerce Health Subcommittee hearing. 

On October 15, 2021, IDSA released revised remarks and a new evidence profile for the use of baricitinib for critically ill patients requiring invasive mechanical ventilation; this update has been endorsed by SIDP.

In legal rulings issued on Sept. 1 and Sept. 20, a federal judge in Texas dismissed all claims a group of Lyme disease patients had brought against the Infectious Diseases Society of America.  

Infections caused by bacteria resistant to multiple antibiotics led to $1.9 billion in health care costs, more than 400,000 days in the hospital and more than 10,000 deaths among older adults across the U.S. in 2017, according to a new study published today in Clinical Infectious Diseases.

IDSA, PIDS and SHEA recommend, in collaboration with the U.S. Centers for Disease Control and Prevention, that clinicians caring for these evacuees consider the varied presentations of medical conditions, including infectious diseases.